Edgewise Therapeutics, Inc. Increase (Decrease) in Employee Related Liabilities
Edgewise Therapeutics, Inc. (EWTX) reported Increase (Decrease) in Employee Related Liabilities of -$3.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $2.90M, a 74.47% increase year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$6.75M.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $4.43M, a 14.52% increase year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $2.36M, a 21.63% increase year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2025 was $2.37M, a 45.56% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $4.36M, a 162.24% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2023 was $1.66M, a 34.66% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2022 was $1.24M, a 23.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.85M 10-Q · filed 2026-08-06 | $578.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$6.75M 10-Q · filed 2026-05-07 | -$2.32M derived: sum of 2 quarters · filed 2026-05-07 | $42.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.79M derived: sum of 2 quarters · filed 2026-02-26 | $8.46M derived: sum of 3 quarters · filed 2026-08-06 | $2.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.02M derived: sum of 2 quarters · filed 2026-08-06 | -$2.06M 10-Q · filed 2025-11-06 | $1.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.42M 10-Q · filed 2026-08-06 | -$550.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$6.08M 10-Q · filed 2026-05-07 | -$2.21M derived: sum of 2 quarters · filed 2026-05-07 | -$269.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.81M derived: sum of 2 quarters · filed 2026-02-26 | $7.13M derived: sum of 3 quarters · filed 2026-02-26 | $4.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.26M derived: sum of 2 quarters · filed 2025-11-06 | $491.00K 10-Q · filed 2025-11-06 | $1.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.45M 10-Q · filed 2025-08-07 | -$164.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.12M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$2.77M 10-Q · filed 2025-05-08 | -$1.48M derived: sum of 2 quarters · filed 2026-02-26 | -$200.00K derived: sum of 3 quarters · filed 2026-02-26 | $851.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.57M derived: sum of 2 quarters · filed 2026-02-26 | $3.62M derived: sum of 3 quarters · filed 2026-02-26 | $1.66M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.33M derived: sum of 2 quarters · filed 2024-11-07 | $376.00K 10-Q · filed 2024-11-07 | $1.70M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$907.00K 10-Q · filed 2024-08-08 | $421.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.10M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.96M 10-Q · filed 2024-05-09 | -$630.00K derived: sum of 2 quarters · filed 2024-05-09 | $50.00K derived: sum of 3 quarters · filed 2024-05-09 | $728.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.01M derived: sum of 2 quarters · filed 2024-02-22 | $2.69M derived: sum of 3 quarters · filed 2024-02-22 | $1.24M 10-K · filed 2024-02-22 |
| 2022-09-30 | $680.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.36M derived: sum of 2 quarters · filed 2023-11-09 | -$93.00K 10-Q · filed 2023-11-09 | $674.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$773.00K 10-Q · filed 2023-08-10 | -$6.00K derived: sum of 3 quarters · filed 2023-08-10 | $651.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.45M 10-Q · filed 2023-05-11 | -$684.00K derived: sum of 2 quarters · filed 2023-05-11 | -$27.00K derived: sum of 3 quarters · filed 2023-05-11 | $674.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $767.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.42M derived: sum of 2 quarters · filed 2023-02-23 | $2.13M derived: sum of 3 quarters · filed 2023-02-23 | $1.62M 10-K · filed 2023-02-23 |
| 2021-09-30 | $657.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.36M derived: sum of 2 quarters · filed 2022-11-03 | $855.00K 10-Q · filed 2022-11-03 | $1.35M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $701.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $198.00K 10-Q · filed 2022-08-04 | $689.00K derived: sum of 3 quarters · filed 2022-08-04 | $919.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$503.00K 10-Q · filed 2022-05-11 | -$12.00K derived: sum of 2 quarters · filed 2022-05-11 | $218.00K derived: sum of 3 quarters · filed 2022-05-11 | $417.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $721.00K derived: sum of 2 quarters · filed 2022-02-24 | $920.00K derived: sum of 3 quarters · filed 2022-02-24 | $842.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $429.00K derived: sum of 2 quarters · filed 2021-11-10 | $351.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $121.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$78.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |